ESMO 2022 | CANTO: improving the quality of life of women treated for localized breast cancer
Fabrice André, MD, PhD, Gustave Roussy Institute, Villejuif, France, provides an overview of the CANcer TOxicities (CANTO) study, which aims to study the chronic toxicities of cancer treatments, focusing on the cohort of woman with localized breast cancer. So far, approximately 13,000 woman with early stage breast cancer have been included and supported throughout the project. The purpose of CANTO Is to improve the quality of life of woman being treated for locally advanced breast cancer through preventing treatment toxicities. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (edited for clarity)
So CANTO is a prospective trial specifically focused on survivorship. It included so far around 13,000 patients with early stage breast cancer. What kind of data are we collecting? So we are collecting, first, all the baseline characteristics, and then during the follow up of patient, we are collecting patient-reported outcome. In addition, we collect large number of samples, the tumor, the blood, the faeces, for example...
So CANTO is a prospective trial specifically focused on survivorship. It included so far around 13,000 patients with early stage breast cancer. What kind of data are we collecting? So we are collecting, first, all the baseline characteristics, and then during the follow up of patient, we are collecting patient-reported outcome. In addition, we collect large number of samples, the tumor, the blood, the faeces, for example. So we have many sample we collected.
What have been the main achievements so far? First, there was a paper in Journal of Clinical Oncology reporting that around 16% of patients are not adherent to endocrine therapy, and that was one of very first study done with blood testing, blood dosage of endocrine therapy.
We had another report in Journal of Clinical Oncology about the return to work. It’s a very important problem, and thanks to control, we could identify the predictive factor for return to work. More recently, one team has focused its work on fatigue, and they can show that they are different trajectories of fatigue, and a large number of patients developing fatigue, and they could develop, again, predictive factor for fatigue. Now we are moving to the integration of biomarker into this cohort, thanks to the large number of samples that we have collected. And of course, the message that is important is that with this cohort, the samples and the data are available for colleagues who want to make their own investigation in this field of survivorship.
Read more...
